Wayne State University, Department of Pharmacology, 540 East Canfield Avenue, Detroit, MI 48201, USA.
J Pharmacol Exp Ther. 2010 Mar;332(3):821-8. doi: 10.1124/jpet.109.160390. Epub 2009 Dec 1.
Tumor cells that are grown in three-dimensional (3D) cell culture exhibit relative resistance to cytotoxic drugs compared with their response in conventional two-dimensional (2D) culture. We studied the effects of targeted agents and doxorubicin on 2D and 3D cultures of human breast cell lines that represent the progression from normal epithelia (modeled by MCF10A cells) through hyperplastic variants to a dysplastic/carcinoma phenotype (MCF10.DCIS cells), variants transformed by expression of activated Ras, and also a basal-subtype breast carcinoma cell line (MDA-MB-231). The results showed the expected relative resistance to the cytotoxic agent doxorubicin in 3D cultures, with greater resistance in normal and hyperplastic cells than in carcinoma models. However, the response to the targeted inhibitors was more complex. Inhibition of mitogen-activated protein kinase kinase (MEK) by either 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) or 2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide (CI-1040, PD184352) produced a similar inhibition of the growth of all the MCF10 cell lines in 2D. In 3D culture, the normal and hyperplastic models exhibited some resistance, whereas the carcinoma models became far more sensitive to MEK inhibition. Increased sensitivity to MEK inhibition was also seen in MDA-MB-231 cells grown in 3D compared with 2D. In contrast, inhibition of phosphatidylinositol 3'-kinase activity by wortmannin had no significant effect on the growth of any of the cells in either 2D or 3D. Our conclusion is that 3D culture models may not only model the relative resistance of tumor cells to cytotoxic therapy but also that the 3D approach may better identify the driving oncogenic pathways and critical targeted inhibitors that may be effective treatment approaches.
与常规二维(2D)培养相比,在三维(3D)细胞培养中生长的肿瘤细胞对细胞毒性药物表现出相对耐药性。我们研究了靶向药物和阿霉素对代表正常上皮细胞(由 MCF10A 细胞模拟)向增生变体发展到发育不良/癌表型(MCF10.DCIS 细胞)、通过表达激活的 Ras 转化的变体以及基底亚型乳腺癌细胞系(MDA-MB-231)的人乳腺细胞系的 2D 和 3D 培养物的影响。结果显示,3D 培养物中对细胞毒性药物阿霉素的预期相对耐药性,正常和增生细胞的耐药性大于癌模型。然而,对靶向抑制剂的反应更为复杂。通过 1,4-二氨基-2,3-二氰基-1,4-双(甲基硫代)丁二烯(U0126)或 2-(2-氯-4-碘-苯基氨基)-N-环丙基甲氧基-3,4-二氟-苯甲酰胺(CI-1040,PD184352)抑制丝裂原活化蛋白激酶激酶(MEK)产生对 MCF10 细胞系在 2D 中的生长的类似抑制。在 3D 培养物中,正常和增生模型表现出一定的耐药性,而癌模型对 MEK 抑制变得更加敏感。在 3D 培养中,与 2D 相比,MDA-MB-231 细胞的生长对 MEK 抑制的敏感性也增加。相比之下,wortmannin 抑制磷酸肌醇 3'-激酶活性对任何细胞在 2D 或 3D 中的生长均无明显影响。我们的结论是,3D 培养模型不仅可以模拟肿瘤细胞对细胞毒性治疗的相对耐药性,而且 3D 方法还可以更好地确定驱动致癌途径和关键靶向抑制剂,这些途径可能是有效的治疗方法。